Vidall Cheryl, Fernández-Ortega Paz, Cortinovis Diego, Jahn Patrick, Amlani Bharat, Scotté Florian
Alcura, Selborne House, Mill Lane, Alton, Hampshire, GU34 2QJ, UK.
Catalan Institute of Oncology, Hospital Duran i Reynals, Gran Via l'Hospitalet 199-203, L'Hospitalet de Llobregat, 08908, Barcelona, Spain.
Support Care Cancer. 2015 Nov;23(11):3297-305. doi: 10.1007/s00520-015-2750-5. Epub 2015 May 8.
Chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) can affect half of oncology patients, significantly impacting daily life. Nausea without vomiting has only recently been thought of as a condition in its own right. As such, the incidence of nausea is often underestimated. This survey investigated the incidence and impact of CINV/RINV in patients compared with estimations of physicians/oncology nurses to determine if there is a perceptual gap between healthcare professionals and patients.
An online research survey of physicians, oncology nurses and patients was conducted across five European countries. Participants had to have experience prescribing/recommending or have received anti-emetic medication for CINV/RINV treatment. Questionnaires assessed the incidence and impact of CINV/RINV, anti-emetic usage and compliance, and attribute importance of anti-emetic medication.
A total of 947 (375 physicians, 186 oncology nurses and 386 patients) participated in this survey. The incidence of nausea was greater than vomiting: 60 % of patients reported nausea alone, whereas 18 % reported vomiting. Physicians and oncology nurses overestimated the incidence of CINV/RINV but underestimated its impact on patients' daily lives. Only 38 % of patients reported full compliance with physicians'/oncology nurses' guidelines when self-administering anti-emetic medication. Leading factors for poor compliance included reluctance to add to a pill burden and fear that swallowing itself would induce nausea/vomiting.
There is a perceptual gap between healthcare professionals and patients in terms of the incidence and impact of CINV/RINV. This may lead to sub-optimal prescription of anti-emetics and therefore management of CINV/RINV. Minimising the pill burden and eliminating the requirement to swallow medication could improve poor patient compliance with anti-emetic regimens.
化疗/放疗引起的恶心和呕吐（CINV/RINV）会影响半数肿瘤患者，对日常生活产生重大影响。无呕吐的恶心直到最近才被视为一种独立的病症。因此，恶心的发生率常常被低估。本次调查旨在研究CINV/RINV在患者中的发生率和影响，并与医生/肿瘤护士的估计进行比较，以确定医疗保健专业人员与患者之间是否存在认知差距。
在五个欧洲国家对医生、肿瘤护士和患者进行了一项在线研究调查。参与者必须有开具/推荐或接受过用于CINV/RINV治疗的止吐药物的经验。问卷评估了CINV/RINV的发生率和影响、止吐药物的使用和依从性，以及止吐药物的属性重要性。
共有947人（375名医生、186名肿瘤护士和386名患者）参与了本次调查。恶心的发生率高于呕吐：60%的患者仅报告有恶心，而18%的患者报告有呕吐。医生和肿瘤护士高估了CINV/RINV的发生率，但低估了其对患者日常生活的影响。只有38%的患者报告在自行服用止吐药物时完全遵循医生/肿瘤护士的指导原则。依从性差的主要因素包括不愿增加服药负担以及担心吞咽本身会引发恶心/呕吐。
医疗保健专业人员与患者在CINV/RINV的发生率和影响方面存在认知差距。这可能导致止吐药物的处方不够理想，从而影响CINV/RINV的管理。尽量减少服药负担并消除吞咽药物的要求可能会改善患者对止吐方案的依从性差的情况。
